Christine Flefleh

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Feng Luo, Zheng Yang, Amy Camuso et al. · Clinical Cancer Research · 2006 · 149 citations

Medicine, Pharmacokinetics, Pharmacology +13

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

Feng Luo, Zheng Yang, Huijing Dong et al. · Cancer Chemotherapy and Pharmacology · 2005 · 87 citations

Medicine, Oncology, Pharmacokinetics +11

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels

Robert A. Wild, Krista Fager, Christine Flefleh et al. · Molecular Cancer Therapeutics · 2006 · 62 citations

Medicine, Oncology, Pharmacology +15

Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.

Rosalyn D. Blumenthal, Chris Waskewich, David M. Goldenberg et al. · PubMed · 2001 · 51 citations

Medicine, Oncology, Pharmacology +16

BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo

Francis Y. Lee, Louis J. Lombardo, Amy Camuso et al. · Cancer Research · 2005 · 41 citations

Medicine, Oncology, Pharmacology +15